Literature DB >> 26862398

Extrahepatic manifestations of chronic hepatitis C virus infection.

Patrice Cacoub1, Cloe Comarmond, Fanny Domont, Léa Savey1, Anne C Desbois, David Saadoun1.   

Abstract

During hepatitis C virus (HCV) chronic infection, extrahepatic manifestations are frequent and polymorphous. This article reports on a large cohort of patients with HCV-related autoimmune or lymphoproliferative disorders, from mixed cryoglobulinemia vasculitis to frank lymphomas. The relationship between HCV infection and such immune-related diseases has been formally demonstrated by epidemiological, clinical, immunological and pathological data, and results of therapeutic trials. More recently, other nonliver-related HCV disorders have been reported, including cardiovascular (i.e. stroke, ischemic heart disease), renal, metabolic and central nervous system diseases. For these manifestations, most evidence comes from large epidemiological studies; there is a need for mechanistic studies and therapeutic trials for confirmation. Beyond the risk of developing liver complications, that is, cirrhosis and liver cancer, patients with HCV infection have an increased risk of morbidity and mortality related to nonliver diseases. HCV chronic infection should be analyzed as a systemic disease in which extrahepatic consequences increase the weight of its pathological burden. The need for effective viral eradication measures is underlined.

Entities:  

Keywords:  extrahepatic manifestations; hepatitis C virus; treatment

Year:  2016        PMID: 26862398      PMCID: PMC4735500          DOI: 10.1177/2049936115585942

Source DB:  PubMed          Journal:  Ther Adv Infect Dis        ISSN: 2049-9361


  124 in total

1.  Hepatitis C virus and atherosclerosis in patients with type 2 diabetes.

Authors:  Michiaki Fukui; Yoshihiro Kitagawa; Naoto Nakamura; Toshikazu Yoshikawa
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

2.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

4.  Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.

Authors:  S Caronia; K Taylor; L Pagliaro; C Carr; U Palazzo; J Petrik; S O'Rahilly; S Shore; B D Tom; G J Alexander
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

5.  Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.

Authors:  Patrick Marcellin; Michel Chousterman; Thierry Fontanges; Denis Ouzan; Michel Rotily; Marina Varastet; Jean-Philippe Lang; Pascal Melin; Patrice Cacoub
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

6.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

Authors:  Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04       Impact factor: 11.382

Review 7.  Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?

Authors:  Salvatore De Vita; Luca Quartuccio; Martina Fabris
Journal:  Autoimmun Rev       Date:  2008-06-25       Impact factor: 9.754

Review 8.  B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review.

Authors:  Eva Negri; D'Anna Little; Mauro Boiocchi; Carlo La Vecchia; Silvia Franceschi
Journal:  Int J Cancer       Date:  2004-08-10       Impact factor: 7.396

9.  Hepatitis C virus infection and the prevalence of renal insufficiency.

Authors:  Lorien S Dalrymple; Thomas Koepsell; Joshua Sampson; Tin Louie; Jason A Dominitz; Bessie Young; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2007-05-30       Impact factor: 8.237

10.  Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis.

Authors:  Benjamin Terrier; Alexandre Karras; Philippe Cluzel; Jean-Philippe Collet; Damien Sène; David Saadoun; Patrice Cacoub
Journal:  Am J Cardiol       Date:  2012-10-30       Impact factor: 2.778

View more
  57 in total

1.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

2.  Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

Authors:  Zong-Han Yao; Wei-Yu Liao; Chao-Chi Ho; Kuan-Yu Chen; Jin-Yuan Shih; Jin-Shing Chen; Zhong-Zhe Lin; Chia-Chi Lin; James Chih-Hsin Yang; Chong-Jen Yu
Journal:  Oncologist       Date:  2017-05-15

Review 3.  Hepatitis C virus: Promising discoveries and new treatments.

Authors:  Juliana Cristina Santiago Bastos; Marina Aiello Padilla; Leonardo Cardia Caserta; Noelle Miotto; Aline Gonzalez Vigani; Clarice Weis Arns
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  Extrahepatic Benefits Achieved With Sustained Virologic Response in Patients With Hepatitis C Virus Infection.

Authors:  Marcelo Kugelmas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-09

5.  Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.

Authors:  Albert Do; Denise A Esserman; Supriya Krishnan; Joseph K Lim; Tamar H Taddei; Ronald G Hauser; Janet P Tate; Vincent Lo Re; Amy C Justice
Journal:  J Gen Intern Med       Date:  2020-04-27       Impact factor: 5.128

6.  Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C.

Authors:  Linh Tran; Jeah Jung; Caroline Carlin; Sunmin Lee; Chen Zhao; Roger Feldman
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 7.  Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Authors:  Sern Wei Yeoh; Alex C N Holmes; Michael M Saling; Ian P Everall; Amanda J Nicoll
Journal:  Hepatol Int       Date:  2018-06-21       Impact factor: 6.047

8.  Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs.

Authors:  Lauren L Knight; Katherine Wagner; Yuridia Leyva; Veronica R Bruce; Kirsten A M White; Yvonne S Talamantes; Brittany Price; Kimberly Page; Martha L Carvour
Journal:  Health Promot Pract       Date:  2018-09-18

9.  Discontinuation of new hepatitis C drugs among Medicare patients.

Authors:  Jeah Jung; Ping Du; Roger Feldman; Thomas Riley
Journal:  Am J Manag Care       Date:  2020-02       Impact factor: 2.229

10.  Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.

Authors:  Bruce S Pyenson; Gabriela Dieguez; Christine Ferro; Maushumi Mavinkurve; Yuri Sanchez Gonzalez
Journal:  Am Health Drug Benefits       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.